Early prediction of drug metabolism and toxicity: Systems biology approach and modeling

Drug Discovery Today

Volumn 9, Issue 3, 2004, Pages 127-135

  Bugrim, Andrej ^a   Nikolskaya, Tatiana ^a   Nikolsky, Yuri ^b  

^a GeneGo bioinformatics software Inc   (United States)

^b CHEMDIV INC   (United States)

Author keywords

ADME Tox; Biochemistry; Drug Discovery; Pharmaceutical Science; Pre clinical prediction; Systems biology; Techniques Methods

Indexed keywords

PYRAZINAMIDE;

BLOOD BRAIN BARRIER; DATA BASE; DNA MICROARRAY; DRUG ELIMINATION; DRUG METABOLISM; HUMAN; MASS SPECTROMETRY; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTION; PROTEOMICS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; COMPUTER SIMULATION; DATABASES, FACTUAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1042302103     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02971-4     Document Type: Review

References (59)

1. Talafous J., et al. META. 2. A dictionary model of mammalian xenobiotic metabolism. J. Chem. Inf. Comput. Sci. 34:1994;1326-1333.
2. Klopman G., et al. META. 1. A program for the evaluation of metabolic transformation of chemicals. J. Chem. Inf. Comput. Sci. 34:1994;1320-1325.
3. Darvas F. Predicting metabolic pathways by logic programming. J. Mol. Graph. 6:1988;80-86.
4. Darvas, F. (1987) MetabolExpert, an expert system for predicting metabolism of substances, in QSAR. In Environmental Toxicology (Keiser, K., ed.), pp. 71-81, Riedel, Dordrecht.
5. Greene N., et al. Knowledge-based expert systems for toxicity and metabolism prediction: DEREK,StAR and METEOR. SAR QSAR Environ. Res. 10:1999;299-314.
6. Judson P.N., et al. Using new reasoning technology in chemical information systems. J. Chem. Inf. Comput. Sci. 36:1996;621-624.
7. Klopman G., et al. META. 3. A genetic algorithm for metabolic transform priorities optimization. J. Chem. Inf. Comput. Sci. 37:1997;329-334.
8. Hayashi S., et al. Genetic polymorphisms in the 5(-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J. Biochem. (Tokyo). 110:1991;559-565.
9. Kato S., et al. Cytochrome P4502E1 (CYP2E1) genetic polymorphism in a case-control study of gastric cancer and liver disease. Pharmacogenetics. 5:1995;S141-S144.
10. Korolev D., et al. Modeling of human cytochrome p450-mediated drug metabolism using unsupervised machine learning approach. J. Med. Chem. 46:2003;3631-3643.
11. de Groot M.J., Ekins S. Pharmacophore modeling of cytochromes P450. Adv. Drug Deliv. Rev. 54:2002;367-383.
12. Lewis D.F., et al. An improved and updated version of the compact procedure for the evaluation of P450-mediated chemical activation. Drug Metab. Rev. 30:1998;709-737.
13. Zhang E.Y., et al. Modeling of active transport systems. Adv. Drug Deliv. Rev. 54:2002;329-354.
14. Ekins S., et al. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther. 301:2002;427-434.
15. Ekins S., et al. A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta. Pharm. Res. 19:2002;1788-1800.
16. Ekins S., Erickson J.A. A pharmacophore for human pregnane X receptor ligands. Drug Metab. Dispos. 30:2002;96-99.
17. Lewis D.F., et al. Further evaluation of COMPACT, the molecular orbital approach for the prospective safety evaluation of chemicals. Mutat. Res. 412:1998;41-54.
18. Beken S., et al. Effects of L-proline on phase I and phase II xenobiotic biotransformation capacities of rat and human hepatocytes in long-term collagen gel cultures. Altern. Lab. Anim. 29:2001;35-53.
19. Chen T.L., et al. Effects of propofol on functional activities of hepatic and extrahepatic conjugation enzyme systems. Br. J. Anaesth. 84:2000;771-776.
20. Jackson H. Baculovirus-mediated high level expression of a human thiopurine methyl transferase. Biochem. Mol. Biol. Int. 38:1996;357-364.
21. Thomas R.S., et al. Identification of toxicologically predictive gene sets using cDNA microarrays. Mol. Pharmacol. 60:2001;1189-1194.
22. Amin R.P., et al. Genomic interrogation of mechanisms underlying cellular responses to toxicants. Toxicology. 27:2002;555-563.
23. Waring J.F., et al. Identifying toxic mechanisms using DNA microarrays. Toxicology. 27:2002;537-550.
24. Kubinyi H. Drug research:myths, hype and reality. Nat. Rev. Drug Discov. 8:2003;665-668.
25. Blackstock W.P., Weir M.P. Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol. 17:1999;121-127.
26. Ho Y., et al. Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature. 415:2002;180-183.
27. Gavin A.C., et al. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature. 415:2002;141-147.
28. Anderson N.L., et al. The effects of peroxisome proliferators on protein abundance in mouse liver. Toxicol. Appl. Pharmacol. 137:1996;75-89.
29. Chevalier S., et al. Proteomic analysis of differential protein expression in primary hepatocytes induced by EGF, tumor necrosis factor or the peroxisome proliferators nafenopin. Eur. J. Biochem. 267:2000;4624-4634.
30. Arce A., et al. Changes in the liver protein pattern of female Wistar rats treated with the hypoglycemic agent SDZ PGU 693. Life Sci. 63:1998;2243-2250.
31. Fountoulakis M., et al. Two-dimensional database of mouse liver proteins: changes in hepatic protein levels following treatment with acetaminophen or its non-toxic regioisomer. Electrophoresis. 21:2000;2148-2161.
32. Kennedy S. The role of proteomics in toxicology: identification of biomarkers of toxicity by protein expression analysis. Biomarkers. 7:2002;269-290.
33. Griffin J.L., et al. Metabolic profiling of genetic disorders: a multi-tissue NMR spectroscopic and pattern recognition study into dystrophic tissue. Anal. Biochem. 293:2001;16-21.
34. Smith L.L. Key challenges for toxicologists in the 21st century. Trends Pharmacol. Sci. 22:2001;281-285.
35. Raamsdonk L.M., et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat. Biotechnol. 19:2001;45-51.
36. Choi B.K., et al. Comparison of Quadropole, Time-of-flight and Fourier Transform mass analyzers for LC-MS applications. LC GC. 19:2001;514-520.
37. Nicholson J.K., et al. Metabonomics: understanding the metabolic responses of living systems to pathological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 29:1999;1181-1189.
38. Vigneau-Calahan K.E., et al. Characterization of diet-dependent metabolic serotypes: analytical and biological variability in rats. J. Nutr. 131:2001;924-932.
39. Beecher C. Metabolomics: the newest of the 'omics' sciences. Innov. Pharm. Technol. 2:2002;57-64.
40. Nicholson J.K., et al. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 1:2002;153-161.
41. Holmes E., et al. Metabonomic classification of genetic variations in toxicological and metabolic responses using probabilistic neural networks. Chem. Res. Toxicol. 14:2001;182-191.
42. Nicholson J.K., Wilson I.D. Understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat. Rev. Drug Discov. 2:2003;668-676.
43. Kanehisha M., et al. The KEGG databases at GenomeNet. Nucleic Acids Res. 30:2002;42-46.
44. Selkov E., et al. MPW: the metabolic pathways database. Nucleic Acids Res. 26:1998;43-45.
45. Gilmore M.S., Ferretti J.J. The thin line between gut commensal and pathogen. Science. 299:2003;1999-2002.
46. Hood L., Galas D. The digital code of DNA. Nature. 421:2003;444-448.
47. Schomburg I., et al. BRENDA, enzyme data and metabolic information. Nucleic Acids Res. 30:2002;47-49.
48. Selkov E., et al. The metabolic pathway collection from EMP: the enzymes and metabolic pathways database. Nucleic Acids Res. 24:1996;26-28.
49. Selkov E. Jr, et al. MPW: the metabolic pathways database. Nucleic Acids Res. 26:1998;43-45.
50. Karp P.D., et al. The metacyc database. Nucleic Acids Res. 30:2002;59-61.
51. Gaasterland T., Selkov E. Reconstruction of metabolic networks using incomplete information. Proc. Int. Conf. Intell. Syst. Mol. Biol. 3:1995;127-135.
52. Covert M.W., et al. Metabolic modeling of microbial strains in silico. Trends Biochem. Sci. 26:2001;179-186.
53. Selkov E., et al. Functional analysis of gapped microbial genomes: amino acid metabolism of Thiobacillus ferrooxidans. Proc. Natl. Acad. Sci. U. S. A. 97:2000;3509-3514.
54. Overbeek R., et al. WIT: integrated system for high-throughput genome sequence analysis and metabolic reconstruction. Nucleic Acids Res. 28:2000;123-125.
55. Rives A.W., Galitski T. Modular organization of cellular networks. Proc. Natl. Acad. Sci. U. S. A. 100:2003;1128-1133.
56. Snel B., et al. The identification of functional modules from the genomic association of genes. Proc. Natl. Acad. Sci. U. S. A. 99:2002;5890-5895.
57. Spirin V., Mirny L.A. Protein complexes and functional modules in molecular networks. Proc. Natl. Acad. Sci. U. S. A. 100:2003;12123-12128.
58. Papastavros T., et al. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ. 167:2002;131-136.
59. Shibata K., et al. Effects of dietary pyrazinamide, an antituberculosis agent, on the metabolism of tryptophan to niacin and of tryptophan to serotonin in rats. Biosci. Biotechnol. Biochem. 65:2001;1339-1346.